Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E177.52 EPS (ttm)0.72 Insider Own0.60% Shs Outstand226.69M Perf Week1.59%
Market Cap28.89B Forward P/E19.56 EPS next Y6.52 Insider Trans-5.27% Shs Float223.19M Perf Month3.15%
Income145.20M PEG9.25 EPS next Q1.18 Inst Own98.80% Short Float2.12% Perf Quarter-19.34%
Sales2.70B P/S10.68 EPS this Y-79.50% Inst Trans-0.01% Short Ratio2.42 Perf Half Y-17.52%
Book/sh35.82 P/B3.56 EPS next Y29.13% ROA1.10% Target Price179.72 Perf Year-36.58%
Cash/sh4.53 P/C28.12 EPS next 5Y19.20% ROE1.80% 52W Range110.56 - 205.29 Perf YTD-33.18%
Dividend- P/FCF54.87 EPS past 5Y5.10% ROI1.60% 52W High-38.46% Beta1.01
Dividend %- Quick Ratio3.00 Sales past 5Y36.90% Gross Margin91.80% 52W Low14.26% ATR3.37
Employees2924 Current Ratio3.50 Sales Q/Q16.80% Oper. Margin22.10% RSI (14)48.64 Volatility2.50% 2.87%
OptionableYes Debt/Eq0.40 EPS Q/Q-10.10% Profit Margin5.40% Rel Volume0.71 Prev Close127.46
ShortableYes LT Debt/Eq0.40 EarningsJul 28 BMO Payout0.00% Avg Volume1.96M Price126.33
Recom1.90 SMA203.34% SMA50-4.34% SMA200-16.87% Volume894,632 Change-0.89%
Jul-13-16Reiterated SunTrust Buy $220 → $197
Jul-13-16Initiated RBC Capital Mkts Outperform $188
Jul-11-16Upgrade Credit Suisse Neutral → Outperform $186 → $165
Jun-27-16Upgrade Citigroup Neutral → Buy
May-09-16Reiterated Barclays Equal Weight $175 → $180
Mar-08-16Downgrade Robert W. Baird Outperform → Neutral $221 → $170
Feb-25-16Initiated Citigroup Buy $165
Feb-04-16Reiterated UBS Buy $222 → $200
Feb-04-16Reiterated Barclays Equal Weight $202 → $175
Jan-20-16Initiated Credit Suisse Neutral
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $225
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Dec-11-15Reiterated Stifel Buy $250 → $245
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-14-15Downgrade Barclays Overweight → Equal Weight $220 → $205
Sep-01-15Initiated Raymond James Strong Buy $225
Jul-31-15Reiterated UBS Buy $220 → $223
Jul-31-15Reiterated Stifel Buy $239 → $257
Jul-31-15Reiterated Brean Capital Buy $213 → $221
Jul-27-15Resumed JP Morgan Overweight
Jul-26-16 09:43AM  Alexion (ALXN) Q2 Earnings: Stock Likely to Disappoint
Jul-25-16 11:05AM  Understanding Improvement in Vertex Pharmaceuticalss PE Multiple
11:05AM  Whats behind the Recent Fall in Alexions Valuation Multiple?
09:05AM  Orkambi Launch Impacts Vertex Pharmaceuticalss Major Revenue Contributor
09:05AM  How Kanuma Addition to Alexions Portfolio Impacts Its Earnings
Jul-23-16 07:01AM  I Just Bought These 4 Fast-Growing Biotech Stocks at Motley Fool
Jul-22-16 01:16PM  Is Vertex Pharmaceuticals Exposed to Drug Pricing Risks?
01:16PM  How Alexion Plans to Fuel Strensiq Sales
01:16PM  How Can Alexion Stay ahead of the Competition with Soliris?
Jul-21-16 04:43PM  Wall Street Looks for Vertex Pharmaceuticals to Break Even in 2Q16
04:20PM  Sorry, You Can't Buy This Hot Biotech -- At Least Not Directly at Motley Fool
03:56PM  Analysts Gauge Alexion Pharmaceuticals Return Potential
03:54PM  Will Alexion Pharmaceuticals 2Q16 Earnings Surprise?
Jul-19-16 04:21PM  Earnings Estimates for These 3 Biotech Giants Should Be Heading Lower -- Here's Why at Motley Fool
Jul-15-16 04:19PM  Biotech: Steak, But No Sizzle at Barrons.com
Jul-14-16 11:07AM  Why Alexion Pharmaceuticals, Inc. Stock Sank 23.5% in June at Motley Fool
09:04AM  Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB) Business Wire
Jul-13-16 04:02PM  Amazon Target Primed; Top Banks Initiated Ahead Of Earnings
01:47PM  Alexion Pharmaceuticals (ALXN) Stock Gets Outperform Rating at RBC Capital
12:58PM  16 Recently Upgraded Stocks (APD,ALXN,ADP,BHI) at Investopedia
11:39AM  Biotech: 'We Would Not Be Surprised to See Volatility Continue' at Barrons.com
11:29AM  [$$] Three Biotech Picks With Pipeline Upside at Barrons.com
05:32AM  Coverage initiated on Alexion Pharma by RBC Capital Mkts
Jul-12-16 01:33PM  Stocks in record territory
10:10AM  Biotechs With Drug Pipelines Closest to Zero Valuation at 24/7 Wall St.
Jul-11-16 10:05AM  The Word on the Street: How Analysts See BioMarin Now
10:05AM  Why Did BioMarins Share Price Tank after Brexit?
10:00AM  Alexion Pharmaceuticals to Report Second Quarter 2016 Results on Thursday, July 28, 2016 Business Wire
09:22AM  Alexion (ALXN) Stock Gains on Ratings Upgrade
08:58AM  Coverage Initiated on Select Biotech Equities
08:50AM  Morning Movers: Alexion Pharma Gains on Upgrade; Alcoa Rises Ahead of Earnings at Barrons.com
08:15AM  Analysts' Actions -- Baker Hughes, ConocoPhillips, GameStop, Toll Brothers and More
01:05AM  A Look at Alexions 2016 Guidance
01:04AM  How Much Upside Potential Does Alexion Have?
Jul-07-16 10:41AM  Brexit Shouldn't Have Much, If Any, Effect on This Sector at Motley Fool
08:30AM  New Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Presented at ICNMD Annual Congress Business Wire
Jul-06-16 11:16AM  Gilead Sciences: 'This Could Be One of the Strongest Quarters in Some Time' at Barrons.com
Jul-02-16 12:40PM  The 10 Worst-Performing S&P 500 Stocks in June
Jun-30-16 03:06PM  ALXN 1210: Another of Alexions Important Pipeline Drugs
Jun-29-16 02:24PM  Behind the Recent Fall in BioMarins Premium Valuation
02:06PM  What Are the Additional Labels for Alexions Soliris?
02:06PM  Why Did Alexion Fall after Brexit?
01:28PM  16 Biopharma Companies Besides Medivation That Are Attractive Targets
Jun-27-16 03:55PM  Why Did Alexions EV-to-EBITDA Multiple Nosedive?
03:55PM  Whats Behind Alexions Price-to-Earnings Premium?
02:24PM  Street Talk: Alexion, Manpower & more
02:06PM  Alexion Pharmaceuticals: Brexit Be Damned; Citigroup Ups to Buy Citing "Dark Sky Valuation" at Barrons.com
08:44AM  Top Analyst Upgrades and Downgrades: Alexion, Barrick Gold, Barclays, Coeur Mining, GW Pharma, SE, AGCO, HSBC, RBS and Many More at 24/7 Wall St.
07:01AM  Effects of Brexit on Pharmaceuticals and the Biotechnology Industry
Jun-24-16 02:41PM  2 Biotech Stocks That Won't Pay a Dividend Anytime Soon, and 1 That Should at Motley Fool -8.56%
01:53PM  Biotech: Buy the Brexit Blowup? at Barrons.com
Jun-22-16 04:04PM  Verifone, Biogen Crash Wednesdays 52-Week Low Club at 24/7 Wall St.
11:38AM  3 Value Stocks Near 52-Week Lows Worth Buying at Motley Fool
Jun-17-16 09:30PM  SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
Jun-16-16 10:10AM  Stock Market News for June 16, 2016
08:35AM  3 Underdog Stocks We're Watching at Motley Fool
Jun-13-16 09:30AM  The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Jun-10-16 01:15PM  4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
07:15AM  Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too
02:30AM  Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH Business Wire
Jun-09-16 01:38PM  Alexion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ALXN) : June 9, 2016
09:07AM  What Caused Alexion Pharmaceuticals Fall?
Jun-08-16 02:21PM  What Helped Incyte Report Growth in 1Q16?
10:10AM  Company News for June 08, 2016
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN) PR Newswire
08:24AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : June 8, 2016
07:11AM  Rev's Forum: Don't Be Seduced by the Market's Dark Side
07:00AM  Trader's Daily Notebook: Gusher for Oil Stocks
Jun-07-16 06:20PM  IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against Alexion Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm Business Wire -10.88%
05:27PM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : June 7, 2016
04:40PM  Amazon Price Target Hiked; GE Started At Neutral; Alexion PT Cut
04:27PM  Alexion shares tumble after drug misses trial goal at CNBC
03:59PM  Here's Why Shares of Biogen and Alexion Tanked On Tuesday at TheStreet
02:03PM  Biotech Smacked Despite Broad U.S. Stock Rally at Barrons.com
01:05PM  Why Alexion Pharmacetuicals Inc. Is Dropping Today at Motley Fool
01:04PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Alexion Pharmaceuticals, Inc. -- ALXN Business Wire
01:01PM  S&P 500 Flirts With All-Time High; Biotechs Weigh On Nasdaq
12:37PM  Trending Tickers: Z, VRX, BIIB, ALXN
12:13PM  Biotech stocks on the move
12:06PM  Stocks Not Having A Good Day: Catalent, Alexion Pharmaceuticals, DryShips, More at Insider Monkey
12:05PM  Alexion Pharmaceuticals: Time to Buy? at Barrons.com
11:49AM  Alexion's Soliris Misses Phase III Primary Efficacy Endpoint
11:32AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Pharmaceuticals, Inc. - ALXN PR Newswire
11:08AM  Stocks Turn Mixed As Biotechs Sicken, Ralph Lauren Chapped
09:45AM  Stocks Open Higher As Oil Rises; Valeant, Alexion, Biogen Dive
Jun-06-16 05:47PM  After-hours buzz: Sarepta, Alexion, Whole Foods & more at CNBC
05:47PM  After Hours: Alexion, Zillow, United Natural Foods, FedEx, Viacom, Hawaiian
05:44PM  Alexion Skids as Muscle Drug Trial Fails to Meet Primary Goal at Bloomberg
04:49PM  Alexion drug misses goal in late-stage trial
04:41PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:37PM  Alexion shares fall after drug study fails to reach main goal at MarketWatch
04:01PM  Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Business Wire
Jun-02-16 10:15AM  Alexion's (ALXN) Rare Disorder Drug Gets EU Orphan Status
Jun-01-16 04:05PM  European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Business Wire
May-31-16 05:44PM  These Billionaires Just Made a Killing on Celator. Here's What Else They've Been Buying at Motley Fool
02:42PM  Why Biotech Stocks Like Alexion May Get Burned at Forbes
10:00AM  Alexion to Present at Upcoming Investor Conferences Business Wire
May-29-16 01:03PM  5 Trade Ideas for Tuesday: Abbott Labs, Alexion Pharma, Lear, M&T Bank and Panera
May-27-16 03:47PM  3 Biotech Stocks to Buy in June at Motley Fool
May-25-16 08:05AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US : May 25, 2016
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moriarty John BEVP & General CounselJun 13Sale135.72918124,59151,360Jun 14 04:50 PM
MACKAY MARTINEVP & Global Head of R&DMay 16Sale139.204,097570,28442,688May 18 04:36 PM
Wagner Heidi LSVP, Global Government AffairsMay 13Sale138.65537,34832,337May 13 05:48 PM
O'Neill JulieEVP. Global OperationsMar 02Sale149.5565197,35736,034Mar 04 06:21 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 29Sale138.9132945,70116,886Mar 01 06:33 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 29Sale138.91547,50141,579Mar 01 06:34 PM
BELL LEONARDDirectorFeb 29Sale138.923,995554,987742,197Mar 01 06:32 PM
Carmichael ClareEVP, Chief HR OfficerFeb 29Sale138.911,312182,25039,742Mar 01 06:32 PM
Moriarty John BEVP & General CounselFeb 29Sale138.911,201166,83352,278Mar 01 06:32 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 29Sale138.91905125,71443,799Mar 01 06:33 PM
Wagner Heidi LSVP, Global Government AffairsFeb 29Sale138.9154775,98432,390Mar 01 06:34 PM
Hallal DavidCEOFeb 29Sale138.932,014279,800191,012Mar 01 06:32 PM
Sinha VikasEVP & CFOFeb 29Sale138.911,122155,862178,740Mar 01 06:33 PM
MACKAY MARTINEVP & Global Head of R&DFeb 29Sale138.911,000138,91046,785Mar 01 06:34 PM
O'Neill JulieEVP. Global OperationsFeb 29Sale138.9166392,09736,685Mar 01 06:33 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 16Sale143.4918726,83336,633Feb 18 06:29 PM
BELL LEONARDDirectorFeb 08Sale138.0911,4741,584,442746,192Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 08Sale138.052,665367,91134,054Feb 08 07:57 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 08Sale138.071,474203,51844,704Feb 08 07:56 PM
Moriarty John BEVP & General CounselFeb 08Sale138.082,633363,57748,501Feb 08 07:58 PM
Hallal DavidCEOFeb 08Sale138.053,946544,763173,026Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 08Sale138.07942130,06629,937Feb 08 07:57 PM
O'Neill JulieEVP. Global OperationsFeb 08Sale138.07778107,41930,348Feb 08 07:55 PM
MACKAY MARTINEVP & Global Head of R&DFeb 08Sale138.091,966271,48140,785Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 08Sale137.613,890535,316171,862Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 05Sale143.501,954280,404175,752Feb 08 07:56 PM
MACKAY MARTINEVP & Global Head of R&DFeb 05Sale141.562,005283,82342,751Feb 08 07:56 PM
O'Neill JulieEVP. Global OperationsFeb 05Sale143.232,080297,91931,126Feb 08 07:55 PM
Wagner Heidi LSVP, Global Government AffairsFeb 05Sale143.14997142,70830,879Feb 08 07:57 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 05Sale143.021,051150,31414,215Feb 08 07:57 PM
Hallal DavidCEOFeb 05Sale141.636,722952,043176,972Feb 08 07:57 PM
Moriarty John BEVP & General CounselFeb 05Sale143.451,969282,44751,134Feb 08 07:58 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 05Sale143.481,970282,66146,178Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 05Sale141.761,993282,53836,719Feb 08 07:57 PM
BELL LEONARDDirectorFeb 05Sale143.122,136305,702757,666Feb 08 07:56 PM
BELL LEONARDDirectorFeb 04Sale143.832,262325,338746,997Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 04Sale143.8420729,77426,949Feb 08 07:57 PM
Hallal DavidCEOFeb 04Sale143.8362990,469142,558Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 04Sale143.8416924,30925,747Feb 08 07:57 PM
Sinha VikasEVP & CFOFeb 04Sale143.83703101,116165,943Feb 08 07:56 PM
BELL LEONARDDirectorDec 29Option Exercise22.9028,968663,367778,227Dec 29 05:03 PM
BELL LEONARDDirectorDec 29Sale190.8028,9685,526,983749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 28Option Exercise22.904009,160749,659Dec 29 05:03 PM
BELL LEONARDDirectorDec 28Sale190.1540076,060749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 24Option Exercise22.905,632128,973754,891Dec 29 05:03 PM
BELL LEONARDDirectorDec 24Sale190.005,6321,070,080749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 17Option Exercise22.9070,0001,603,000819,259Dec 21 05:43 PM
BELL LEONARDDirectorDec 17Sale187.6970,00013,137,985749,259Dec 21 05:43 PM
NORBY R DOUGLASDirectorDec 11Sale187.7145,4428,530,12432,481Dec 15 05:36 PM
Moriarty John BEVP & General CounselDec 11Sale182.73943172,31141,340Dec 15 05:35 PM
Veneman Ann MDirectorDec 11Sale187.48895167,7953,252Dec 15 05:36 PM
BELL LEONARDDirectorDec 11Sale187.5621,3193,998,527727,940Dec 15 05:36 PM
Islam SaqibEVP, Chief Strat & Port. Off.Dec 08Sale190.00950180,50036,385Dec 08 07:36 PM
BELL LEONARDDirectorDec 08Sale188.2070,00013,173,840849,088Dec 08 07:36 PM
BELL LEONARDDirectorNov 25Option Exercise22.9035,000801,500954,088Nov 30 05:42 PM
BELL LEONARDDirectorNov 25Sale181.8935,0006,366,288919,088Nov 30 05:42 PM
Thiel CarstenEVP, Chief Commercial OfficerNov 10Sale173.343,000520,02028,018Nov 12 06:25 PM
PARVEN ALVIN SDirectorNov 02Sale178.73895159,9634,645Nov 04 05:29 PM
Islam SaqibEVP, Chief Strat & Port. Off.Nov 02Sale180.00975175,50037,335Nov 04 05:29 PM
BELL LEONARDDirectorNov 02Sale180.1235,0006,304,200919,088Nov 04 05:29 PM
Islam SaqibEVP, Chief Strat & Port. Off.Oct 26Sale168.441,558262,43038,310Oct 29 05:17 PM
Thiel CarstenSVP, EMEA & Asia PacificSep 10Sale169.18812137,37129,018Sep 10 08:45 PM
BELL LEONARDDirectorSep 09Sale180.101,050189,105919,088Sep 10 08:46 PM
Miller EdwardSVP, Chief Compliance OfficerSep 09Sale179.5536665,7156,464Sep 10 08:45 PM
O'Neill JulieEVP. Global OperationsSep 02Sale171.76647111,12921,443Sep 10 08:46 PM
Carmichael ClareEVP, Chief HR OfficerSep 01Sale168.6230551,42927,156Sep 03 07:08 PM
Hallal DavidCEOAug 07Sale190.0132962,513143,187Aug 11 05:53 PM
Carmichael ClareEVP, Chief HR OfficerAug 07Sale190.0116330,97227,461Aug 11 05:53 PM
Moriarty John BEVP & General CounselAug 07Sale190.0113525,65142,283Aug 11 05:53 PM
BELL LEONARDDirectorAug 07Sale190.011,003190,580919,088Aug 11 05:53 PM
Moriarty John BEVP & General CounselAug 05Option Exercise92.6520,0001,853,00042,428Aug 05 06:08 PM
Moriarty John BEVP & General CounselAug 05Sale198.4410,0101,986,37732,418Aug 05 06:08 PM
BELL LEONARDDirectorAug 04Sale196.522,200432,344920,091Aug 05 06:08 PM
Sinha VikasEVP & CFOAug 04Sale196.52675132,651166,646Aug 05 06:08 PM
Carmichael ClareEVP, Chief HR OfficerAug 04Sale196.5218536,35627,624Aug 05 06:09 PM
Hallal DavidCEOAug 04Sale196.52612120,270143,516Aug 05 06:09 PM
MACKAY MARTINEVP & Global Head of R&DAug 03Option Exercise130.2943,5005,667,48876,393Aug 05 06:09 PM
MACKAY MARTINEVP & Global Head of R&DAug 03Sale196.5243,5008,548,41832,893Aug 05 06:09 PM